Monitor the November 21 meeting for any dissident votes against director nominees, which would signal governance discontent. The heavy related-party concentration with TheraCour (controlled by the CEO) and the married CEO/CFO structure are structural governance risks that could become focal points if the company faces financial distress or needs external capital.
Price Chart
Executive Summary
NanoViricides filed its definitive proxy statement for the 2026 Annual Meeting, seeking re-election of three directors (Todd Rokita, Makarand Jawadekar, Brian Zucker), ratification of auditor EisnerAmper LLP, and approval of an adjournment proposal. The filing is routine with no shareholder proposals, contested elections, or compensation votes. Key governance concerns include a classified board, combined Chairman/CEO role held by Anil Diwan, and extensive related-party transactions with TheraCour Pharma (controlled by Diwan) including $829K in accounts payable and $1.995M in annual development costs.
Key Facts
- Annual Meeting scheduled for November 21, 2026; record date September 21, 2026
- Three director nominees: Todd Rokita (Class I), Makarand Jawadekar and Brian Zucker (Class II), all incumbents
- Auditor ratification: EisnerAmper LLP, audit fees $283,000 for FY2026 vs $207,000 for FY2025
- CEO Anil Diwan total compensation: $440,052 (salary $400,000 + stock awards $40,052) for FY2026
- CFO Meeta Vyas total compensation: $135,445 (salary $129,600 + stock awards $5,845) for FY2026
- TheraCour Pharma (controlled by CEO Diwan) holds 74.2% of Series A Preferred stock and 21.1% of voting power
- Accounts payable to TheraCour: ~$829,000 at June 30, 2026; development costs charged by TheraCour: ~$1,995,000 for FY2026
- No Say-on-Pay vote, no shareholder proposals on the ballot
- Board has 4 members, 3 independent; classified board with 2-year staggered terms
- CEO Diwan and CFO Vyas are married; Diwan also controls TheraCour Pharma (~90% ownership)
Financial Impact
Audit fees increased 37% YoY to $283,000; related-party payables to TheraCour grew 42% to $829,000; development costs from TheraCour were $1.995M for FY2026
Risk Factors
- CEO/CFO are married, creating a concentration of control and potential conflicts
- TheraCour Pharma (controlled by CEO) holds 74.2% of Series A Preferred stock, giving outsized voting power (21.1% of total votes)
- Accounts payable to TheraCour increased 42% YoY to $829K, with $1.995M in annual development costs billed by related party
- Classified board structure limits shareholder ability to change board composition quickly
- No Say-on-Pay vote or shareholder proposals, limiting direct shareholder feedback mechanisms
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEF 14A Filing (Primary) | 0001104659-26-114606 |
| Document: 0001104659-26-114606-index-headers.html | 0001104659-26-114606 |
| Document: 0001104659-26-114606-index.html | 0001104659-26-114606 |
| Document: 0001104659-26-114606.txt | 0001104659-26-114606 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 424B5 | $1.51 | awaiting T+60 | — | $1.36 (−9.93%) |
Oct 8, 2026 18d ago | DEF 14A | $1.31 | awaiting T+60 | — | $1.36 (+3.82%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▲ +3.90% | ▲ +7.95% | $1.36 (+11.69%) |
Jul 27, 2026 13w ago | 424B5 | $1.54 $1.48 | ▼ −3.90% | ▼ −7.95% | $1.36 (−11.69%) |
Jun 29, 2026 17w ago | EFFECT | $1.37 $1.51 | ▼ −10.22% | ▼ −6.60% | $1.36 (+0.73%) |
Jun 16, 2026 19w ago | EFFECT | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.36 (+0.00%) |
Jun 15, 2026 19w ago | S-3 | $1.36 $1.02 | ▼ −25.00% | ▼ −26.86% | $1.36 (+0.00%) |
Jun 5, 2026 20w ago | S-3 | $1.43 $1.17 | ▲ +18.18% | ▲ +21.69% | $1.36 (+4.90%) |
May 18, 2026 23w ago | 424B5 | $1.51 $1.37 | ▲ +9.27% | ▲ +14.12% | $1.36 (+9.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers